Jarrett Jennifer bought 12,500 shares of Damora Therapeutics, Inc. at $20.23 for $253k on Sep 25, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
Director, President and CEO
Director, President and CEO
Filed Sep 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$252,875Shares × reported price
Shares traded
12,500Ordinary Shares
Price per share
$20.23Reported price. Read footnotes for ranges.
% of reported position traded
2.5%This security and ownership context
Holdings after
512,500Direct
Trade date
Sep 25, 2026Buy
Filed
Sep 28, 2026, 7:00 AM ET3-day reporting delay
Accession
0001193125-26-403355Code P · Transaction 230096
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 500,000 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

DMRA price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
DMRA · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago1w ago1d ago
Returns since7d −2.6%30d +5.8%90d180d1y

Footnotes in full

F1: Represents shares purchased on the open market at prevailing market prices using personal funds. F2: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $20.10 to $20.40, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3: Includes 500,000 restricted stock units ("RSUs") previously granted to the Reporting Person. Each RSU represents the right to receive, at settlement, one ordinary share of the Issuer.